Developing First-In-Class Therapeutics to Protect the Vision of Patients with Retinal Disease

We are thrilled to announce our upcoming CEO knowledge sharing during the April 12th MSQ Webinar Series. Our distinguished guest speaker, CEO David Esposito of ONL Therapeutics, will be presenting on "Developing First-In-Class Therapeutics to Protect the Vision of Patients with Retinal Disease." 

By advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway, ONL Therapeutics is pioneering an entirely new approach to preserve sight. It is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss, a leading cause of blindness and an unaddressed medical need. 

Co-host: MSQ Ventures and BioAroundWorld 

Guest Speaker: David Esposito, CEO, ONL Therapeutics  

Moderator: Echo Hindle-Yang, CEO, MSQ Ventures  

Date: Wednesday, April 12th, 2023 

Time: 9pm – 10pm BJT 

9am – 10am ET 

Webinar Format: 

• Webinar is 1 hour in length including: 

• 10-15 min MSQ intro w/ CEO  

• 30-minute company presentation  

• 10–15-minute Q&A 

Register Here: https://lnkd.in/ekPrS8RW

* After the webinar, attendees will have an opportunity to set up a 1-1 session with the guest speaker post event via MSQ